Page 103 - 2021_05-Haematologica-web

Endothelial injury, F-actin and vitamin-D binding protein
extracted and submitted for RNAseq analysis. Gene expression at day 100 was compared with expression at day 0.
Glucose stress test
Macrophage polarization was examined by measurement of extracellular acidification rate (ECAR) using Seahorse technology. Briefly, normal PBMC were incubated overnight with sera collect-
ed at days 0 and 100 from two HSCT recipients. Cells were har- vested and replated before performance of a glucose stress test and metabolic analysis.
Vitamin D binding protein glycosylation studies
Vitamin D binding protein glycosylation studies are detailed in the Online Supplementary Appendix.
AB
CD
Figure 1. The association of detectable filamentous actin and vitamin D binding protein with clinical outcomes of hematopoietic stem cell transplant. (A) Cumulative incidence of transplant-associated thrombotic microangiopathy (TA-TMA) in hematopoietic stem cell transplant (HSCT) recipients with and without detectable filamentous actin (F-actin) (61% vs. 37%, P=0.03). (B) Cumulative incidence of non-relapse mortality (NRM) in HSCT recipients with and without detectable F-actin (29% vs. 13%, P=0.028). (C) Cumulative incidence of TA-TMA in HSCT recipients with vitamin D binding protein (VDBP) levels above and below the median (10% vs. 31%, P=0.01). (D) Cumulative incidence of NRM in HSCT recipients with VDBP levels above and below the median (0% vs. 15%, P=0.002).
Table 2. Outcomes of bone marrow transplant in pediatric hematopoietic stem cell transplant recipients according to vitamin D binding protein level at days 30 and 100.
Outcome
TA-TMA
GvHD
NRM
VDBP> Median
10%
8%
8%
Day 30 VDBP VDBP<Median P
31% 0.01
21% 0.09
10% 0.1
VDBP> Median
0%
3%
0%
Day 100 VDBP VDBP<Median P
7% 0.45
18% 0.04
15% 0.002
VDBP: vitamin D binding protein; TA-TMA: transplant-associated thrombotic microangiopathy; GvHD: graft versus host disease; NRM: non-relapse mortality
haematologica | 2021; 106(5)
1323